Undiagnosed HIV Prevalence Among Adults and Adolescents in the United States at the End of 2006

被引:156
作者
Campsmith, Michael L. [1 ]
Rhodes, Philip H. [1 ]
Hall, H. Irene [1 ]
Green, Timothy A. [1 ]
机构
[1] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA
关键词
undiagnosed HIV prevalence; risk behaviors; disease disparities; ANTIRETROVIRAL THERAPY; PERSONS AWARE; DRUG-USERS; HIGH-RISK; PREVENTION; INFECTION; TRANSMISSION; SERVICES; SURVIVAL; BEHAVIOR;
D O I
10.1097/QAI.0b013e3181bf1c45
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: To describe adults/adolescents (age 13 years and older) living with undiagnosed HIV infection in the United States at the end of 2006. Methods: HIV prevalence and percentage undiagnosed were estimated from cumulative HIV incidence using an extended back-calculation model (using both HIV and AIDS data, the time of first diagnosis with HIV, and disease severity at diagnosis) and estimated cumulative deaths. Results: An estimated 1,106,400 adults/adolescents (95% confidence interval = 1,056,400-1,156,400) were living with HIV in the United States at the end of 2006; overall, 21.0% (232,700; 95% confidence interval = 221,200-244,200) were undiagnosed. Whites had the lowest percentage undiagnosed (18.8%) compared with Hispanics/Latinos (21.6%), blacks/African Americans (22.2%), American Indians/Alaska Natives (25.8%), and Asians/Pacific Islanders (29.5%; all P < 0.001). Persons with a behavioral risk of injection drug use (IDU) had the lowest percentage undiagnosed (female IDU: 13.7% and male IDU: 14.5%); men exposed through heterosexual contact had the highest (26.7%) followed by men who have sex with men (23.5%). Conclusions: Differences in undiagnosed HIV were evident across demographic and behavior groups. Effective testing programs and early access to treatment and prevention services are necessary to reduce undiagnosed HIV infections and HIV prevalence.
引用
收藏
页码:619 / 624
页数:6
相关论文
共 48 条
  • [1] Aalen OO, 1997, STAT MED, V16, P2191, DOI 10.1002/(SICI)1097-0258(19971015)16:19<2191::AID-SIM645>3.0.CO
  • [2] 2-5
  • [3] Sifakis F., 2005, Morbidity and Mortality Weekly Report, V54, P597
  • [4] [Anonymous], 1999, MMWR Recomm Rep, V48, P1
  • [5] [Anonymous], 1993, MMWR
  • [6] [Anonymous], 2003, MMWR-MORBID MORTAL W, V2, P329
  • [7] [Anonymous], SAS WIND COMP PROGR
  • [8] Challenges in the development of an HIV-1 vaccine
    Barouch, Dan H.
    [J]. NATURE, 2008, 455 (7213) : 613 - 619
  • [9] Becker N G, 1997, Stat Methods Med Res, V6, P24, DOI 10.1191/096228097670368368
  • [10] Changes in the risk of death after HIV seroconversion compared with mortality in the general population
    Bhaskaran, Krishnan
    Hamouda, Osamah
    Sannes, Mette
    Boufassa, Faroudy
    Johnson, Anne M.
    Lambert, Paul C.
    Porter, Kholoud
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 300 (01): : 51 - 59